Updated on 15 June 2012
In 2011, Dr. Reddy's became the only Indian pharmaceutical company to celebrate the 10th anniversary of listing at the New York Stock Exchange. Significant focus of the company in the US market with limited competition harnessed 13 percent increase in revenue from North America in 2010-11. Dr. Reddy's launched 11 new products in US in 2010-11, of which five products experienced limited competition.
Revenues from Russia and Commonwealth of Independent States (CIS) countries grew by 19 percent whereas in Europe, the company faced fall in the market by 13 percent.
The company is targeting a leadership position in global generics and pharmaceuticals services, and in active ingredients business.